Percutaneous Autologous Bone-marrow Grafting for Open Tibial Shaft Fracture (IMOCA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00512434|
Recruitment Status : Completed
First Posted : August 7, 2007
Last Update Posted : May 4, 2017
The treatment of open tibial shaft fracture is often complicated by delayed union or non-union. The objective of this study is to evaluate the efficacy of autologous concentrated bone-marrow to accelerate healing of open tibial shaft fractures and to reduce the need for secondary intervention.
In a prospective, randomized, controlled, single-blind study, 186 patients with an open tibial will be randomized to receive either the standard of care (fixation by nail or external fixator and routine soft-tissue management), or the standard of care with percutaneous injection, one month after fracture, of autologous concentrated bone-marrow. Randomization will be stratified by severity of the open wound. The primary outcome measure will be the proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve months post-fracture.
|Condition or disease||Intervention/treatment||Phase|
|Tibial Fractures Fractures, Open||Procedure: Osteosynthesis||Not Applicable|
This study will be conducted at 13 University Hospitals in France. The protocol has been approved by the institutional review board. After written informed consent, patients will be randomized, in the days after the fracture in 2 groups of 93 patients : 1) the control group (standard of care only: fixation by nail or external fixator and routine soft-tissue management) and 2) the study group (standard of care with percutaneous injection, one month after fracture, of autologous concentrated bone-marrow). Randomization will be stratified by severity of the open wound and by center. For the wound, strata A comprise Gustilo-Anderson types I, II and III-A and strata B, type III-B.
For the study group, the injection is scheduled at 1 month ± 5 days after the fracture. The techniques have been described by Hernigou (J Bone Joint Surg Am, 2006; 88(sup 1 part 2): 322-327). There are 3 steps: marrow aspiration (300 - 500 g) from iliac crest under general anesthesia, centrifugation in cell therapy unit to obtain a concentrated buffy coat of about 50 ml containing progenitor cells and other mononuclear cells, percutaneous injection in the fracture site of 20-30 ml of the buffy coat under fluoroscopy control.
Apart from the injection, the standard of care is the same for the 2 groups. Patients will be followed for 12 months, with assessments at 1, 2, 3, 6, 9 and 12 months.
All analysis will be based on the intent to treat the population. The primary outcome measure will be the proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve months post fracture. An independent panel of surgeons will evaluate all secondary procedure with the potential of promoting fracture-healing.
An independent evaluation of fracture union will be conducted by a radiology panel blinded to treatment allocation and all other patient data.
An outcome will be considered to be successful when the fracture heal, according to the investigator, without secondary intervention and is radiographically united during patient follow-up.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||85 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Injection of Concentrated Autologous Bone-marrow (IMOCA) and Bone Union of Open Tibial Shaft Fracture: Randomized Study to Assess Efficiency of IMOCA in Addition to Standard of Care.|
|Study Start Date :||September 2007|
|Actual Primary Completion Date :||September 2012|
|Actual Study Completion Date :||September 2013|
Active Comparator: Control in arm fields
Standard treatment Intervention no'Osteosynthesis'
Nail or external fixator Intervention 'Osteosynthesis'
Intervention 'Osteosynthesis' Percutaneous autologous bone-marrow grafting - surgical technique (ref: Hernigou Ph et al J Bone Joint Surg Am ,2006; 88 (sup 1 part 2): 322-327
Nail or external fixator Intervention 'Osteosynthesis'
- Proportion of patients requiring secondary intervention because of delayed union or nonunion within twelve month post fracture. [ Time Frame: one year ]
- Relation between the number of the progenitor available injected with concentrated bone marrow aspirated and the rate of bone union. [ Time Frame: one year ]
- Comparison of the rate of complications between the 2 groups. [ Time Frame: one year ]
- Economic impact study. [ Time Frame: one year ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00512434
|Angers, France, 49933|
|UH Besançon Jean Minjoz|
|Besancon, France, 25030|
|UH Brest Cavale Blanche|
|Brest, France, 29200|
|UH Clermont Ferrand Gabriel Montpied|
|Clermont Ferrand, France, 63 000|
|UH Grenoble Michallon Hospital|
|Grenoble, France, 38043|
|UH Grenoble South Hospital|
|Grenoble, France, 38434|
|UH Nancy Central Hospital|
|Nancy, France, 54000|
|UH Nantes Hôtel Dieu|
|Nantes, France, 44|
|UH Pitié Salpétrière AH HP|
|Paris, France, 75013|
|UH Tours CHRU Trousseau|
|Tours, France, 37 044|
|Principal Investigator:||Philippe Rosset, Pr||Service d'orthopédie II - CHRU de Tours|